Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics (Nasdaq: CADL) reported its Q1 2024 financial results and corporate highlights. The company showcased positive survival data from its ongoing phase 2 clinical trial of CAN-2409 in pancreatic cancer, with a median overall survival of 28.8 months compared to 12.5 months for the control group. CAN-2409 also received FDA Fast Track and Orphan Drug Designations.
Topline survival data for CAN-2409 in NSCLC will be presented at ASCO on June 3, 2024. The company's enLIGHTEN™ platform revealed a new immunotherapy candidate at the AACR Annual Meeting.
Financially, Candel's Q1 2024 research and development expenses decreased to $4.1 million from $5.5 million in Q1 2023. General and administrative expenses also decreased to $3.8 million from $4.2 million. The net loss stood at $8.2 million, down from $8.8 million. Cash reserves were $25.7 million as of March 31, 2024, providing sufficient funds into Q4 2024.
- Positive phase 2 survival data for CAN-2409 in pancreatic cancer.
- Median overall survival of 28.8 months vs. 12.5 months for control group.
- CAN-2409 received FDA Fast Track and Orphan Drug Designations.
- Upcoming topline data presentation at ASCO on June 3, 2024.
- New immunotherapy candidate unveiled from enLIGHTEN™ platform.
- Reduced research and development expenses to $4.1 million.
- Reduced general and administrative expenses to $3.8 million.
- Net loss decreased to $8.2 million from $8.8 million.
- Cash reserves dropped to $25.7 million from $35.4 million.
- Net loss of $8.2 million reported for Q1 2024.
- Change from net income to net expense due to decreased fair value of warrants and lower interest income.
Insights
The financial results released by Candel Therapeutics reveal several key insights. The company's research and development expenses decreased by
However, the net loss for the quarter still stands at
For retail investors, while the cost-saving measures and improved financial management are positive, the consistent net loss and dwindling cash reserves warrant caution. The company will need to demonstrate significant advancements or secure additional funding to ensure longer-term sustainability.
Candel's ongoing clinical trials and recent designations from the FDA are noteworthy. The updated phase 2 data for CAN-2409 in pancreatic cancer show a substantial improvement in median overall survival (28.8 months vs. 12.5 months) and a significant increase in survival rates at both 24 and 36 months in the treated group. These results are promising and underscore the potential efficacy of CAN-2409 in extending patient survival for borderline resectable PDAC.
Additionally, the phase 2 topline data for CAN-2409 in non-small cell lung cancer (NSCLC) will be presented at the ASCO meeting, marking an important milestone for the company. The lack of new safety signals highlights the treatment's favorable safety profile, which is important for regulatory approval and future commercial success.
While these clinical advancements are promising, the long-term success will depend on forthcoming phase 3 results and potential FDA approval. Investors should monitor upcoming data releases closely for further validation of these findings.
The announcement of Candel’s progress with their enLIGHTEN™ Discovery Platform and the introduction of a new first-in-class immunotherapy candidate present significant future opportunities. The development of such innovative therapies has the potential to address significant unmet medical needs in the cancer treatment landscape.
Particularly, the creation of tertiary lymphoid structures could revolutionize treatment approaches by enhancing the body's immune response against tumors. This could place Candel at the forefront of cancer immunotherapy research, potentially leading to lucrative partnerships or acquisition interests from larger biopharmaceutical companies.
However, it is important to recognize that these are still preclinical findings. The path to commercialization involves numerous stages of clinical trials and regulatory hurdles. Hence, while the innovation pipeline is robust, investors need to remain patient and cautious, understanding that substantial revenues from these developments may take years to materialize.
- Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer
- Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024
- On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024
NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
“It was a catalyst-rich first quarter for Candel, marked by significant advances across both our clinical and preclinical programs,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “Notably, as our clinical data mature with long-term follow up, we are beginning to observe highly differentiated results in long-term survival of patients treated with our viral immunotherapies. An example of these clinical results was recently shared in an update of the phase 2 randomized clinical trial of CAN-2409 in patients with borderline resectable pancreatic cancer, where a notable improvement in overall survival, in patients treated with CAN-2409 plus standard of care chemoradiation, was demonstrated compared to chemoradiation alone. The FDA granted CAN-2409 both Fast Track Designation and Orphan Drug Designation for treatment of patients with pancreatic ductal adenocarcinoma to improve median overall survival and treatment of pancreatic cancer, respectively, providing steady momentum to advance this promising investigational treatment for patients with significant unmet medical need.”
Dr. Tak continued, “We are also excited to announce that topline overall survival data from our phase 2 clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer and an inadequate response to immune checkpoint inhibitors will be presented at the upcoming ASCO meeting in Chicago on Monday, June 3, 2024.”
“In addition to our advances in the clinic, we have made great progress with our enLIGHTENTM Discovery Platform. In April 2024, we presented our second drug candidate from this platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures, in a late-breaking presentation at the American Association for Cancer Research (AACR) Annual Meeting. We believe this preclinical candidate offers groundbreaking potential in the treatment of cancer,” continued Dr. Tak. “We expect to release additional preclinical and clinical data in the coming year, consistent with our commitment to innovation and patient care.”
First Quarter 2024 & Recent Highlights
- Program Updates
- CAN-2409 – Pancreatic Cancer
- In early April, announced positive updated survival data, from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).
- Data showed notable improvements in estimated median overall survival (mOS) of 28.8 months after experimental treatment with CAN-2409 versus 12.5 months in control group.
- At 24 months, survival rate was
71.4% in CAN-2409 treated patients versus16.7% in the control group after chemoradiation. At 36 months, estimated survival was47.6% in the CAN-2409 group versus16.7% in the control group. - No new safety signals were observed, providing further support that multiple injections of CAN-2409 have been generally well tolerated to date, with no dose-limiting toxicities and no cases of pancreatitis reported.
- Previous analysis of resected tumors showed dense aggregates of immune cells, including CD8+, cytotoxic tumor infiltrating lymphocytes and dendritic cells, in PDAC tissue after CAN-2409 administration, confirming activation of a robust antitumoral immune response.
- Data showed notable improvements in estimated median overall survival (mOS) of 28.8 months after experimental treatment with CAN-2409 versus 12.5 months in control group.
- Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CAN-2409 for the treatment of pancreatic cancer.
- In early April, announced positive updated survival data, from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).
- CAN-2409 – Non-small cell lung cancer (NSCLC)
- Announced a poster titled “Overall survival after treatment with CAN- 2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with inadequate response to ICI” was accepted for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and will be presented by Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania, on June 3, 2024 in Chicago, IL.
- Announced a poster titled “Overall survival after treatment with CAN- 2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with inadequate response to ICI” was accepted for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and will be presented by Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania, on June 3, 2024 in Chicago, IL.
- CAN-3110 – Recurrent High-Grade Glioma (rHGG)
- Received Fast Track Designation from the FDA for CAN-3110 for the treatment of patients with rHGG to improve OS.
- Announced during the 5th Glioblastoma Drug Development Summit in Boston that six patients have been treated with multiple injections (up to six injections) of CAN-3110 in cohort C of the ongoing phase 1b clinical trial, reporting a favorable safety and tolerability profile.
- Announced a Trial-in-Progress poster, titled “Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM)” was accepted for the 2024 ASCO Annual Meeting, and will be presented by David A. Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director, Center for Neuro-Oncology at Dana Farber Cancer Institute, on June 1, 2024, in Chicago, IL.
- Received Fast Track Designation from the FDA for CAN-3110 for the treatment of patients with rHGG to improve OS.
- enLIGHTEN™ Discovery Platform
- Presented preclinical data at the AACR Annual Meeting unveiling the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures (TLS), being developed as a novel therapeutic for solid tumors.
- Presented preclinical data at the AACR Annual Meeting unveiling the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures (TLS), being developed as a novel therapeutic for solid tumors.
- CAN-2409 – Pancreatic Cancer
Anticipated Milestones
- Phase 2 topline OS data for CAN-2409 in NSCLC to be presented at ASCO on June 3, 2024
- Updated Phase 1b data (Arm C) for CAN-3110 in rHGG expected in H2 2024
- Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer expected in Q4 2024
- Phase 3 topline disease-free survival data for CAN-2409 in localized intermediate/high-risk prostate cancer expected in Q4 2024
Financial Results for First Quarter Ended March 31, 2024
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss for the first quarter of 2024 was
Cash Position: Cash and cash equivalents, as of March 31, 2024, were
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable Pancreatic Ductal Adenocarcinoma PDAC (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s programs, the ability of CAN-2409 to improve the median overall survival of patients with PDAC; the ability of CAN-3110 to improve the median overall survival of patients with recurrent HGG; expectations regarding the potential benefits conferred by Orphan Drug Designation and Fast Track Designation; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company’s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC) including the Company’s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Kyle Evans
Account Director
ICR Westwicke
CandelPR@westwicke.com
| Candel Therapeutics, Inc. Consolidated Statements of Operations (in thousands, except share and per share amounts) (Unaudited) | ||||||||
| THREE MONTHS ENDED MARCH 31, | ||||||||
| 2024 | 2023 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 4,102 | $ | 5,469 | ||||
| General and administrative | 3,800 | 4,164 | ||||||
| Total operating expenses | 7,902 | 9,633 | ||||||
| Loss from operations | (7,902 | ) | (9,633 | ) | ||||
| Other income (expense): | ||||||||
| Grant income | — | 12 | ||||||
| Interest income | 320 | 711 | ||||||
| Interest expense | (646 | ) | (609 | ) | ||||
| Change in fair value of warrant liability | 7 | 724 | ||||||
| Total other income (expense), net | (319 | ) | 838 | |||||
| Net loss and comprehensive loss | $ | (8,221 | ) | $ | (8,795 | ) | ||
| Net loss per share, basic and diluted | $ | (0.28 | ) | $ | (0.30 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 29,197,537 | 28,919,810 | ||||||
| Candel Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) | ||||||||
| MARCH 31, 2024 (Unaudited) | DECEMBER 31, 2023 | |||||||
| Cash and cash equivalents | $ | 25,713 | $ | 35,413 | ||||
| Working capital (1) | 13,599 | 22,613 | ||||||
| Total assets | 31,217 | 41,201 | ||||||
| Warrant liability | 909 | 916 | ||||||
| Total other liabilities | 24,329 | 27,540 | ||||||
| Accumulated deficit | (145,249 | ) | (137,028 | ) | ||||
| Total stockholders equity | $ | 5,979 | $ | 12,745 | ||||
| (1) Working capital is calculated as current assets less current liabilities | ||||||||
FAQ
What were Candel Therapeutics' financial results for Q1 2024?
What are the latest clinical trial results for CAN-2409 in pancreatic cancer?
When will Candel Therapeutics present topline data for CAN-2409 in NSCLC?
What are the anticipated milestones for Candel Therapeutics in 2024?
What is the cash position of Candel Therapeutics as of Q1 2024?
